Compare MHH & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | ACHV |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.7M | 167.6M |
| IPO Year | N/A | N/A |
| Metric | MHH | ACHV |
|---|---|---|
| Price | $7.20 | $4.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 30.5K | ★ 590.2K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,657,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $6.20 | $1.84 |
| 52 Week High | $16.00 | $5.78 |
| Indicator | MHH | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 52.73 |
| Support Level | $6.96 | $4.57 |
| Resistance Level | $7.70 | $4.97 |
| Average True Range (ATR) | 0.56 | 0.31 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 52.73 | 57.31 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.